SCHEMBL7081965

SCHEMBL7081965

Cc1ccccc1C1(C=O)C2CC3CC(C2)CC1C3

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.34
HDAC4 P56524 1/20 0.34
P2RX7 Q99572 3/20 0.33
TSHR P16473 2/20 0.33
ALDH1A1 P00352 1/20 0.33
ACHE P22303 1/20 0.33
ALOX12 P18054 1/20 0.32
SIGMAR1 Q99720 3/20 0.31
OPRM1 P35372 1/20 0.30
HSD11B2 P80365 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL790543 0.77 SIGMAR1 (0.37) HSD11B1HDAC4P2RX7TSHRACHE
SCHEMBL6897685 0.74 HSD11B1 (0.38) HSD11B1HDAC4P2RX7SIGMAR1OPRM1
SCHEMBL6682404 0.72 HSD11B1 (0.50) HSD11B1
SCHEMBL6897911 0.70 ALDH1A1 (0.35) HSD11B1HDAC4P2RX7TSHRALDH1A1
Hydrochloric Acid SCHEMBL6899621 0.69 HSD11B1 (0.40) HSD11B1P2RX7SIGMAR1GRIN2DGRIN3B
SCHEMBL6686003 0.68 HSD11B1 (0.40) HSD11B1P2RX7SIGMAR1GRIN2DGRIN3B
SCHEMBL6933296 0.68 SIGMAR1 (0.37) HSD11B1HDAC4P2RX7SIGMAR1GRIN2D
SCHEMBL9721521 0.67 HSD11B1 (0.42) HSD11B1P2RX7TSHRALDH1A1SIGMAR1
Hydrochloric Acid SCHEMBL6685252 0.67 HSD11B1 (0.39) HSD11B1P2RX7SIGMAR1GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL6930722 0.67 SIGMAR1 (0.36) HSD11B1HDAC4P2RX7SIGMAR1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003064372-A1 2-ADAMANTYLALKYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2003-08-07 WO disclosed